Medscape (01/13/12) Mulcahy, Nick
The FDA has issued a warning to healthcare professionals about the lymphoma drug brentuximab (Adcetris, Seattle Genetics). Two new cases of progressive multifocal leukoencephalopathy (PML), which is a rare but serious brain infection, have been reported. Because of the seriousness of PML, which can result in death, a new boxed warning highlighting this risk has been added to the drug label. In addition, a contraindication was added, warning against the use of brentuximab with the cancer drug bleomycin because of the increased risk for pulmonary toxicity.

Read the complete article